title: Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia.
abstract: Atorvastatin is a powerful new synthetic 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor currently in clinical use. Its effects on plasma levels of factor VII were examined in 30 hyperlipidemic patients. After 12 weeks of atorvastatin treatment, factor VII activity (FVIIc) and factor VII antigen (FVIIag) levels had decreased by 13% (p < 0.0001) and 12% (p < 0.0001), respectively. The decreased concentrations of serum triglycerides correlated with decreases in FVIIc levels (r = 0.54, p = 0.0023) and FVIIag levels (r = 0.59, p = 0.0006) at 12 weeks of treatment with atorvastatin. No significant changes were seen in activated factor VII (FVIIa) levels. Plasma concentrations of fibrinogen were slightly, but not significantly, increased at 12 weeks. No significant changes were seen in plasminogen activator inhibitor-1 levels. The effects of atorvastatin on FVII may contribute to a decreased thrombotic potential, resulting in fewer thromboembolic events, including a reduction in coronary heart disease.
authors.affiliation: Department of Laboratory Sciences, School of Health Science, Kanazawa University, Japan. eriko@med3.m.kanazawa-u.ac.jp
authors.forename: Eriko
authors.initials: E
authors.lastname: Morishita
authors.forename: Shinji
authors.initials: S
authors.lastname: Minami
authors.forename: Chizuko
authors.initials: C
authors.lastname: Ishino
authors.forename: Masanori
authors.initials: M
authors.lastname: Kanno
authors.forename: Chika
authors.initials: C
authors.lastname: Uotani
authors.forename: Hidesaku
authors.initials: H
authors.lastname: Asakura
authors.forename: Tamotsu
authors.initials: T
authors.lastname: Matsuda
authors.forename: Shinji
authors.initials: S
authors.lastname: Nakao
mesh_terms: D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D000941:Antigens / Q000378:metabolism*; D000069059:Atorvastatin; D001786:Blood Glucose; D005167:Factor VII / Q000378:metabolism*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006487:Hemostasis / Q000187:drug effects; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism; D007519:Isoantigens / Q000097:blood; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage*; D012307:Risk Factors; D013927:Thrombosis / Q000453:epidemiology / Q000517:prevention & control; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D000941:Antigens; D001786:Blood Glucose; D006538:Heptanoic Acids; D007519:Isoantigens; D011758:Pyrroles; D014280:Triglycerides; C042580:factor VII clotting antigen; D005167:Factor VII; D005340:Fibrinogen; D000069059:Atorvastatin